Enforcement Report - Week of July 10, 2024
Asahi Kasei moves to buy Calliditas for more than $1B
The National Pharmaceutical Pricing Authority (NPPA) has revised the ceiling price of asthma inhaler drug combination formoteral 6 mcg and budesonide 400 mcg dry power inhaler (DPI) under the provisions of suo-moto correction, after three companies submitted their representations.
LAVAL, QC / ACCESSWIRE / May 23, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced additional Canadian public drug plan listings for Pr UCERIS ® (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults. 1
A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers.
LAVAL, QC / ACCESSWIRE / April 3, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the first public drug plan listings for PrUCERIS® (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults.1
Mankind enters pact to distribute AstraZeneca's anti-asthma drug Symbicort
Calliditas announces an seven year orphan drug exclusivity period for TARPEYO®
Takeda wins US approval for first oral drug for eosinophilic esophagitis